Sapu Nano Doses First Patient in Phase 1b Trial of IV Everolimus Formulation
Event summary
- First patient dosed in Phase 1b trial of Sapu003, an IV Deciparticle™ formulation of everolimus, on May 13, 2026.
- Trial (NCT07369505) evaluates safety, tolerability, and preliminary anti-tumor activity in advanced mTOR-sensitive solid tumors.
- Two cohorts: HR-positive/HER2-negative breast cancer (combination therapy) and renal cell carcinoma/other solid tumors (monotherapy).
- Dose escalation follows Bayesian Optimal Interval design with planned levels of 5 mg/m², 7.5 mg/m², and 10 mg/m².
The big picture
Oncotelic and Sapu Nano are testing whether IV delivery of everolimus can overcome the limitations of oral formulations, including variable absorption and dose-limiting toxicity. The trial's success could expand the therapeutic potential of mTOR inhibition in oncology, particularly for patients with advanced solid tumors. The collaboration underscores the trend of biotech partnerships aiming to enhance drug delivery through nanomedicine platforms.
What we're watching
- Clinical Efficacy
- Whether Sapu003's IV formulation demonstrates improved exposure control and anti-tumor activity compared to oral everolimus.
- Regulatory Pathway
- The pace at which the Phase 1b trial progresses and whether it supports future regulatory filings.
- Partnership Strategy
- How Oncotelic and Sapu Nano leverage their collaborative ecosystem to advance Sapu003 through development.
Related topics